A/Prof Colman Taylor is a healthcare reimbursement, health economics, and policy expert with extensive experience across government, industry, and academia. He is a trusted advisor to major industry associations and a strong advocate for patient rights. Colman holds academic roles at The George Institute and UNSW, contributing to global thought leadership in health economics and health technology assessment (HTA).  

A/Prof Colman Taylor joined HTAnalysts in 2014 and was part of a management buy-out in 2016, helping transform the company into a leader in healthcare consultancy. Over his tenure, Colman has provided strategic oversight for more than 500 projects across Australia and the Asia Pacific, working with start-ups, global pharmaceutical firms, digital health innovators, and medical technology companies. He has personally contributed to over 100 reimbursement submissions and economic models, securing funding for transformative therapies and technologies.

Colman serves as a strategic advisor to leading industry associations, including Medicines Australia, the Medical Technology Association of Australia (MTAA), and Pathology Technology Australia (PTA). As an inaugural board member of the Australian Genomics Coalition, he is dedicated to advancing precision medicine and equitable access to genomics. He has played a pivotal role in shaping health policy and HTA reform, co-leading reports presented in Parliament House and contributing to innovative models of healthcare funding.

In academia, Colman leads the Health Economics Program at The George Institute and is a Conjoint Associate Professor at UNSW. His research focuses on health economics in critical care, social impact assessments, and policy-driven evaluations. He has authored more than 50 peer-reviewed publications, attracted over $18 million in funding, and contributed to impactful initiatives such as the inaugural HTA Summit and national health economic guidelines.

Colman’s work extends beyond publications to real-world impact, including creating pathways for subsidized access to cutting-edge treatments, influencing HTA policy reform, and mentoring the next generation of health economics leaders. As Past-President of the Australian ISPOR Committee, Colman continues to drive collaboration between academia, industry, and government, advancing patient access and value-based healthcare across the region.